Scientists in the U.K. have used genome mining to identify bacterial species capable of producing novel polyene antifungal compounds that are both more effective and have a more benign side effect profile than approved polyenes such as amphotericin and nystatin.
Tahrget Therapeutics Ltd. has patented substituted adefovir compounds acting as viral DNA polymerase inhibitors that are potentially useful for the treatment of Epstein-Barr virus infections.
Immune-based strategies to achieve HIV remission are increasingly focusing on ways to boost the body’s ability to control persistent viral reservoirs. Among these approaches, natural killer (NK) cells could be genetically engineered to enhance their ability to recognize and eliminate HIV-infected cells and overcome viral evasion mechanisms. Researchers discussed this emerging strategy at the 26th International AIDS Conference (AIDS 2026), which is taking place July 26-31, 2026, in Rio de Janeiro, Brazil.
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological imprint. At the 26th International AIDS Conference (AIDS 2026), researchers reported persistent abnormalities affecting the gut, cardiovascular system, metabolism and immune function despite effective viral control.
Decoy Therapeutics Inc. has announced in vitro activity by one of its Designable Multi-Antiviral (D-MAV) candidates against wild-type Zaire Ebola virus in testing conducted at the Texas Biomedical Research Institute.
Monkeypox virus (MPXV), which causes mpox disease in humans, comprises two clades: the Central African clade I (with a case fatality rate of about 11%) and the West African clade II (with a case fatality rate of about 4%). The differences in virulence among MPXV clades in humans warrant further investigation; however, a critical gap is the lack of small-animal models for comparing IIa vs. IIb clades.
Abera Bioscience AB has announced, together with clinical partner Radboud University Medical Center, the submission of a clinical trial application in the Netherlands to initiate a phase I trial of its serotype-independent pneumococcal vaccine candidate AB-01.12.
Outer membrane vesicles (OMVs), naturally released by gram-negative bacteria, are promising platforms for mucosal vaccines due to their immunostimulatory properties and ability to display antigens. Abera Bioscience AB previously developed an OMV platform using genetically engineered bacteria with covalent antigen decoration via Spycatcher/Tag technology.
The HIV vaccine field is increasingly focusing on inducing broadly neutralizing antibodies (bNAbs) that can recognize the virus’s genetic diversity. Recent experimental approaches include germline-targeting vaccines, sequential immunization strategies, mRNA-based immunogens, and nanoparticle platforms displaying engineered HIV envelope (Env) trimers. Several studies published in 2025 and 2026 how these designs guide antibody maturation in humans and generate broad neutralizing responses in nonhuman primates, although no HIV vaccine has yet demonstrated protective efficacy in large clinical trials.
RSS
